The Wistar Institute

Contact Info:

3601 Spruce Street

Philadelphia, PA 19104

https://www.wistar.org/resources/genomics-facility/

Grants and Identifiers:

RRID: RRID:SCR_010205

Instrumentation:

Services Provided:

Relevant Publications:

1.) Colevas AD, Talebi Z, Winters E, Even C, Lee VH, Gillison ML, Khan SA, Lu R, Pinsky BA, Soldan SS, Vladmirova O, Lieberman PM, Messick TE (2025 Mar 3). First-in-Human clinical trial of a small molecule EBNA1 inhibitor, VK-2019, in patients with Epstein-Barr positive nasopharyngeal cancer, with pharmacokinetic and pharmacodynamic studies Clinical cancer research : an official journal of the American Association for Cancer Research, 31(5), 815-823. . PMCID: 11915201.

2.) Liu Y, Liao L, An C, Wang X, Li Z, Xu Z, Liu J, Liu S (2021 Apr 21). α-Enolase Lies Downstream of mTOR/HIF1α and Promotes Thyroid Carcinoma Progression by Regulating CST1 Frontiers in Cell and Developmental Biology, 9(), 670019. . PMCID: 8097056.

3.) Li Y, Li Q, Gu J, Qian D, Qin X, Li D (2020 Oct). Exosomal prostate-specific G-protein-coupled receptor induces osteoblast activity to promote the osteoblastic metastasis of prostate cancer Translational Cancer Research, 9(10), 5857-5867. . PMCID: 8798947.

Description:

Core facility that provides the following services: Microarray services, RNA amplification service, ABI 7900 Real-time qPCR service, Capillary DNA sequencing and microsatellite analysis, Illumina HiSeq 2000 sequencing service, Illumina Genome Analyzer services. The Wistar Genomics Facility serves as a hub for consultation and scientific interactions relating to nucleic-acid based methods and provides expertise and support to insure the best possible use of emerging nucleic-acid technologies. In addition to consultation and collaboration with Wistar Cancer Center members, the Facility provides services to the greater scientific community. The establishment of this facility was supported in part by an NCI Cancer Center Support Grant and equipment grants from the Commonwealth of Pennsylvania, The Pew Charitable Trusts and the National Cancer Institute.